Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Befotertinib after Chemo in EGFR-mutated NSCLC post-3rd gen TKI
NCT07181499Phase 2Recruiting
- Sponsor
- Betta Pharmaceuticals
- Start
- Sep 2025
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of befotertinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Started Sep 2025; status: recruiting.
02
Drugs
befotertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07181499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07181499.